Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Current Deferred Revenue (2022 - 2023)

Historic Current Deferred Revenue for Avalo Therapeutics (AVTX) over the last 2 years, with Q1 2023 value amounting to $111000.0.

  • Avalo Therapeutics' Current Deferred Revenue changed N/A to $111000.0 in Q1 2023 from the same period last year, while for Mar 2023 it was $111000.0, marking a year-over-year change of. This contributed to the annual value of $88000.0 for FY2022, which is N/A changed from last year.
  • Avalo Therapeutics' Current Deferred Revenue amounted to $111000.0 in Q1 2023.
  • Over the past 5 years, Avalo Therapeutics' Current Deferred Revenue peaked at $442000.0 during Q3 2022, and registered a low of $88000.0 during Q4 2022.